Earnings Call Summary | ATS Corp(ATS.US) Q1 2025 Earnings Conference
Earnings Call Summary | ATS Corp(ATS.US) Q1 2025 Earnings Conference
The company achieved a gross margin of 29.9%, up by 168 basis points from the previous year, credited to advantageous acquisitions and favorable revenue mix.The following is a summary of the ATS Corporation (ATS) Q1 2025 Earnings Call Transcript:
以下是ATS公司（ATS）2025年第一季度業績會簡報：
Financial Performance:
金融業績：
ATS Corporation reported Q1 2025 revenue at $694 million, a decrease of 8% from the previous year, primarily due to lower transportation revenues.
Despite the revenue decline, adjusted earnings from operations were at $86 million.
The company achieved a gross margin of 29.9%, up by 168 basis points from the previous year, credited to advantageous acquisitions and favorable revenue mix.
Order bookings for Q1 were strong at $817 million, representing an 18% year-over-year increase, driven by organic growth in life sciences and acquisitions.
ATS公司報告2025年第一季度營業收入爲69400萬美元，比上年同期下降8%，主要是由於運輸營收下降所致。
儘管營收下降，調整後的經營利潤爲8600萬元。
該公司毛利率爲29.9%，比上年同期增加了168個點子，歸因於有利的收購和收入組合。
Q1訂單預訂強勁，爲81700萬美元，同比增長18％，主要由於生命科學領域的有機增長和收購所推動。
Business Progress:
業務進展：
ATS Corporation saw its second highest bookings quarter in its history due to strong performance in the life sciences and consumer products sectors.
Significant growth in service and product sales contributed to the overall impressive bookings.
The company continues its expansion in life sciences with a backlog of $990 million, the highest in its history, leading to a 26% increase year-over-year.
With the acquisition of Paxiom, ATS looks to leverage customer synergies and enhance its offerings in food technologies and packaging.
The company remains focused on digital transformation with ongoing developments in its PA Facts platform and the addition of AI-based monitoring systems in its product lineup.
由於在生命科學和消費品行業表現強勁，ATS公司觀察到了其歷史上第二大預訂季度。
服務和產品銷售的顯着增長對整體預訂產生了重要貢獻。
該公司在生命科學業務方面繼續擴張，其歷史上最高的積壓訂單達到99000萬美元，同比增長26％。
通過收購Paxiom，ATS旨在利用客戶協同效應，並增強其食品技術和包裝方面的產品。
該公司繼續專注於數字化轉型，在其PA Facts平台上進行不斷的開發，並在其產品陣容中加入基於人工智能的監控系統。
Opportunities:
機會：
Strong growth in life sciences and the addition of Paxiom to the portfolio presents an opportunity to increase market presence and diversify offerings.
Continuing investments in sustainable technologies and the development of customer-centric solutions such as CABLIblue for sustainable packaging signify an ongoing commitment to meeting evolving customer sustainability requirements.
生命科學領域的強勁增長和Paxiom的加入使得增強市場地位和多樣化產品成爲可能。
繼續投資可持續技術和開發以客戶爲中心的解決方案，例如可持續包裝的CABLIblue，表明對滿足不斷髮展的客戶可持續性要求的承諾。
Risks:
風險：
The expected decline in transportation revenue and consequent adjustments in the EV business reflect a strategic shift and possible ongoing challenges in this market segment.
預計運輸收入下降以及EV業務的相應調整反映出戰略轉變和該市場領域可能面臨的持續挑戰。
More details: ATS Corp IR
更多詳情：ATS公司IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
